VISEN Pharmaceuticals (FRA:T06) Change In Inventory: €-6.97 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:T06 VISEN Pharmaceuticals FRA:T06
7 GF Score
Price €2.06
! 5 Warning Signs
View Full Analysis

What is VISEN Pharmaceuticals Change In Inventory?

VISEN Pharmaceuticals FRA:T06 7 Change In Inventory is €-6.97 Mil as of Jun. 2026. GuruFocus rates FRA:T06 with a GF Score™ of 7/100. The stock has 5 warning signs investors should review.

VISEN Pharmaceuticals's change in inventory for the quarter that ended in Jun. 2026 was €-6.97 Mil. It means VISEN Pharmaceuticals's inventory increased by €6.97 Mil from Dec. 2025 to Jun. 2026 .

VISEN Pharmaceuticals's change in inventory for the fiscal year that ended in Dec. 2025 was €-0.19 Mil. It means VISEN Pharmaceuticals's inventory increased by €0.19 Mil from Dec. 2024 to Dec. 2025 .

VISEN Pharmaceuticals's Total Inventories for the quarter that ended in Jun. 2026 was €7.17 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. VISEN Pharmaceuticals's Days Inventory for the quarter that ended in Jun. 2026 was 317.84.

Inventory Turnover measures how fast the company turns over its inventory within a year. VISEN Pharmaceuticals's Inventory Turnover for the quarter that ended in Jun. 2026 was 0.57.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. VISEN Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Jun. 2026 was 0.83.

VISEN Pharmaceuticals  (FRA:T06) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

VISEN Pharmaceuticals's Days Inventory for the quarter that ended in is calculated as:

Days Inventory=Average Total Inventories/Cost of Goods Sold*Days in Period
=3.6765/2.111*365 / 2
=317.84

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

VISEN Pharmaceuticals's Inventory Turnover for the quarter that ended in Jun. 2026 is calculated as

Inventory Turnover=Cost of Goods Sold / Average Total Inventories
=2.111 / 3.6765
=0.57

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

VISEN Pharmaceuticals's Inventory to Revenue for the quarter that ended in Jun. 2026 is calculated as

Inventory-to-Revenue=Average Total Inventories / Revenue
=3.6765 / 4.425
=0.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

VISEN Pharmaceuticals Change In Inventory Related Terms

VISEN Pharmaceuticals Change In Inventory Historical Data

* Premium members only.

The historical data trend for VISEN Pharmaceuticals's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

VISEN Pharmaceuticals Change In Inventory Chart

VISEN Pharmaceuticals Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Change In Inventory
0.00 0.00 0.00 -0.19

VISEN Pharmaceuticals Semi-Annual Data
Dec22 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Change In Inventory Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 -6.97
FRA:T06
7GF Score
VISEN Pharmaceuticals FRA:T06
Change In Inventory is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

VISEN Pharmaceuticals Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-6.97 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Inventory →
What does a Change In Inventory of €-6.97 Mil mean?
VISEN Pharmaceuticals (FRA:T06) has a Change In Inventory of €-6.97 Mil as of Jun. 2026. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for VISEN Pharmaceuticals and its competitors.
Is VISEN Pharmaceuticals' Change In Inventory too high?
VISEN Pharmaceuticals' current Change In Inventory is €-6.97 Mil. Overall, VISEN Pharmaceuticals has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does VISEN Pharmaceuticals' Change In Inventory compare to ZTS?
VISEN Pharmaceuticals' Change In Inventory of €-6.97 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Inventory for a Drug Manufacturers company?
A good Change In Inventory depends on the Drug Manufacturers industry context. However, Change In Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Inventory mean?
A high Change In Inventory can signal that a stock is expensive relative to its fundamentals. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for VISEN Pharmaceuticals and its competitors. VISEN Pharmaceuticals's current Change In Inventory is €-6.97 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VISEN Pharmaceuticals stock overvalued right now?
VISEN Pharmaceuticals (FRA:T06) has a current Change In Inventory of €-6.97 Mil. The current Change In Inventory is €-6.97 Mil. VISEN Pharmaceuticals' overall GF Score™ is 7/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Inventory calculated?
Change In Inventory is calculated from a company's financial statements. For VISEN Pharmaceuticals (FRA:T06), the current Change In Inventory is €-6.97 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

VISEN Pharmaceuticals Business Description

Other Exchanges 02561:Hong Kong
Address 69 Jiuzhang Road, Suite 3-108, Floor 3, Building B, Hengtai Lixiang Chuangxin Tower, Suzhou, CHN
VISEN Pharmaceuticals is a late-stage, near-commercialization biopharmaceutical company focused on providing treatments in selected endocrinology diseases in China. It has one Core Product and two other pipeline drug candidates. Its Core Product, lonapegsomatropin, is a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency (PGHD), a common short stature in patients aged under 18 caused by insufficient growth hormone. TransCon CNP (navepegritide), one of its key drug candidates, is a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia (ACH), a short-limbed dwarfism that results in severe skeletal complications and comorbidities.
7GF Score

Get the complete analysis for FRA:T06

Change In Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.06
Price